Risk Stratification and Selection of Management Strategy for Localized Prostate Cancer
For some patients with localized prostate cancer, the treatment approach is determined by patient and disease characteristics. For others, advanced risk stratification with gene expression profiling or AI-derived digital histopathology biomarkers can help identify those who may derive greater or lesser absolute benefit from a given treatment, thus informing treatment decisions and reducing the chances of over- or under-treatment. Clinicians need to understand when these tools have the possibility to change management, so that only patients who will benefit undergo testing.
Target Audience
This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, PAs, pharmacists, and other health care professionals who manage patients with cancer.
Learning Objectives
Following this program, participants should be able to:
- Identify patient and disease characteristics that should be considered when recommending disease management approaches for patients with localized prostate cancer.
- Discuss strategies to refine risk stratification in appropriate patients with localized prostate cancer.
Alice Yu, MD, MPH
Moffitt Cancer Center
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Faculty Disclosures
The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Thomas W. Flaig, MD
Agensys, Inc.: Grant/Research Support
Astellas Pharma US, Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Grant/Research Support
Aurora Oncology: Equity Interest/Stock Options; Intellectual Property Rights
Bristol Myers Squibb: Grant/Research Support
Criterium, Inc.: Consulting Fee; Scientific Advisor
Genentech, Inc.: Grant/Research Support
Janssen Pharmaceutica Products, LP: Grant/Research Support; Scientific Advisor
Merck & Co., Inc.: Grant/Research Support
sanofi-aventis U.S.: Grant/Research Support
SeaGen: Grant/Research Support
Alice Yu, MD, MPH
AngioDynamics: Product/Speakers Bureau
Novo Nordisk A/S: Equity Interest/Stock Options
NCCN Staff Disclosures
The planner listed below has the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Crystal Denlinger, MD, FACP
2seventy bio: Grant/Research Support
AbbVie, Inc.: Grant/Research Support
Bluebird bio: Grant/Research Support
Bristol Myers Squibb: Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Genentech, Inc: Grant/Research Support
GSK: Grant/Research Support
Pfizer Inc: Grant/Research Support
sanofi-aventis U.S.: Grant/Research Support
None of the other planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 0.75 contact hour, 0.75 of which are pharmacotherapeutic contact hours.
Pharmacists
NCCN designates this knowledge-based continuing education activity for 0.75 contact hour (0.075 CEUs) of continuing education credit. UAN: JA4008196-0000-24-063-H01-P
PAs
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credit. Approval is valid until March 1, 2025. PAs should only claim credit commensurate with the extent of their participation.
Available Credit
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 ANCC Pharmacology Contact Hours
- 0.75 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing